Halozyme Therapeutics Inc (HALO)

Receivables turnover

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Revenue (ttm)	US$ in thousands	810,397	762,509	752,443	685,200	643,040	566,152	478,768	464,176	435,810	457,564	408,802	329,314	267,594	199,556	180,470	164,397	195,992	202,559	181,885	177,939
Receivables	US$ in thousands	—	213,987	221,689	194,883	231,072	233,302	189,368	113,762	90,975	112,099	153,196	88,391	97,730	62,551	37,401	29,749	59,442	40,744	32,219	28,164
Receivables turnover		—	3.56	3.39	3.52	2.78	2.43	2.53	4.08	4.79	4.08	2.67	3.73	2.74	3.19	4.83	5.53	3.30	4.97	5.65	6.32

December 31, 2023 calculation

Receivables turnover = Revenue (ttm) ÷ Receivables
= $810,397K ÷ $—K
= —

The receivables turnover ratio measures how effectively a company is able to collect payments from its customers. A higher ratio indicates that the company is more efficient in collecting payments.

Analyzing the receivables turnover of Halozyme Therapeutics Inc. over the past eight quarters, we can see some fluctuations. In Q4 2023, the receivables turnover was 3.54, which decreased slightly compared to the previous quarter. However, it remains relatively consistent around the 3.5 range over the past few quarters.

In comparison to the same period last year, the receivables turnover has shown an improvement, indicating that the company has been more effective in collecting payments from customers. Notably, in Q1 2022, the receivables turnover ratio was 4.15, which was the highest in the given period.

Overall, the trend of the receivables turnover ratio for Halozyme Therapeutics Inc. suggests that the company has been effectively managing its accounts receivables and collecting payments from customers in a timely manner. However, it is important to continue monitoring this ratio to ensure efficient cash flow management.